

Conclusions: SVac viral vectors preferentially target the liver without signs of major adverse effect in rodents and non-human primates. Low expression levels of PINS mediated by pSVac delivery is more efficient in inducing immune tolerance as compared to PPINS. We anticipate that SVPINS may be a promising strategy to induce tolerance and prevent development of hyperglycemia without adverse immunogenicity issue caused

by other vector vehicles.

Funding: This work was funded by Amarna Therapeutics and by grants from ISCIII co-funded by Fondos FEDER (PI13/00593 to BRG).